X4 Pharmaceuticals Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2012)

Organization Overview

First Clinical Trial
2016
NCT02667886
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

X4 Pharmaceuticals | X4 Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Mavorixafor (9 trials)

Drugs in Phase 2 Trials (3)

Key: X4 Pharmaceuticals (2) Acquired (1)

axitinib (inlyta) (1 trial)

fontolizumab (1 trial)

nivolumab (opdivo) (1 trial)

Drugs in Phase 1 Trials (2)

ibrutinib (imbruvica) (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Melanoma (Phase 1)

Neutropenia (Phase 1)

Syndrome (Phase 3)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 6